| 2.61 0.025 (0.97%) | 10-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.13 | 1-year : | 3.29 |
| Resists | First : | 2.68 | Second : | 2.81 |
| Pivot price | 2.62  |
|||
| Supports | First : | 2.46 | Second : | 2.04 |
| MAs | MA(5) : | 2.55  |
MA(20) : | 2.64 |
| MA(100) : | 2.47 |
MA(250) : | 2.3 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 34.3 |
D(3) : | 23.5 |
| RSI | RSI(14): 48.8 |
|||
| 52-week | High : | 3.19 | Low : | 1.64 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PLX ] has closed above bottom band by 46.4%. Bollinger Bands are 21.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.68 - 2.69 | 2.69 - 2.71 |
| Low: | 2.56 - 2.57 | 2.57 - 2.59 |
| Close: | 2.59 - 2.61 | 2.61 - 2.63 |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Tue, 27 Oct 2026
Protalix BioTherapeutics, Inc. (PLX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Mon, 26 Oct 2026
Protalix BioTherapeutics to Present at the Stifel 2026 Healthcare Conference - Yahoo Finance
Fri, 23 Oct 2026
Protalix BioTherapeutics, Inc. (DE) Estimates – AMEX:PLX - TradingView
Thu, 15 Oct 2026
A Hungarian fund manager reports a stake above 5% in Protalix BioTherapeutics (PLX). - Stock Titan
Tue, 08 Sep 2026
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences - PR Newswire
Wed, 12 Aug 2026
Protalix BioTherapeutics, Inc. 2026: Revenue $19.9M, EPS $0.05— 10-Q Summary - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|